Gapping up
In reaction to strong earnings/guidance/SSS: M +6.7%, (outlines cost reduction initiatives to support continued profitable sales growth, upgraded to Outperform from Mkt Perform at BMO Capital Mkts), MG +6.5%, NVMI +5.8%, (receives over $20 million in orders from several leading foundries; expects Q4 results to fall in the higher range of its guidance), ITMN +4.4%, FRED +4.2%, (engages financial advisors to explore strategic opportunities to enhance shareholder value; guides Q4 EPS below consensus), SVU +3.1%, (ticking higher), RT +2.3%, EHTH +2.3%, COST +1.3%, URBN +0.3%, (reports 2 month Holiday comparable sales +3% YoY), .
M&A news: MCK +4% (McKesson makes best and final offer for Celesio, increasing offer price to EUR 23.50), FNSR +0.2% (Finisar to acquire u2t Photonics AG).
A few Brazil names are higher: OIBR +3%, CZZ +1.7%, TEF +1.6%, BBVA +1.5%
Other news: ICPT +114.1% (01/09 announces NASH Primary endpoint met: FLINT trial stopped early for efficacy based on highly statistically significant improvement in liver histology), CRDC +57.4% (receives 510(k) Clearance For MicroCutter XCHANGE 30 Cutting/Stapling Device), SQNM +13.8% (announces issuance of European patent for novel methods of detecting fetal aneuploidy),SGMO +13.6% BIIB +0.7% (Biogen Idec and Sangamo announce exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin), FRO +10.6% (still checking), TGB +4.2% (announces 35% increase in annual copper production), GALE+4.2% (continued strength), FRX +3.5% (Barron's profiles positive view on Forest Labs), YPF +2.9% (following late sell-off), ATHX +2% (has been granted patents from the Japan Patent Office for several inventions involving its proprietary cell therapy technology), NOK +1.7% (still checking), ACT +1.6% (generic version of Micardis receives FDA approval), GSK +1.5% (gains accelerated FDA approval for combination use of Mekinist and Tafinlar ), RYAAY +1.3% (still checking), JWN +1.2% (following M guidance/news), GG +1.2% ( achieves 2013 gold production forecasts; record Q4 production), F +1% (Increases Quarterly Dividend 25% in 2014 Q1 to $0.125/share, up from $0.10/share), DDD +0.9% (announced that will.i.am, global entertainer, entrepreneur and philanthropist, joined 3DS as its Chief Creative Officer), NVS +0.6% (higher despite Attorney General Eric Schneiderman announced that his office has filed a lawsuit; also may face Japan probe over its drug advertising, according to reports), BMY +0.5% (Bristol-Myers and AstraZeneca confirm FDA approval of Farxiga), AMZN +0.5% (reports more than a billion units worldwide were ordered from Marketplace Sellers this year), AIG +0.4% (extends tax asset protection plan), S +0.3% (spiked into the close on TMUS halt, downgraded to Hold from Buy at Deutsche Ban).
Analyst comments: ANGI +7.3% (upgraded to Strong Buy from Outperform at Raymond Jame), WWAV +3.3% (ticking higher, upgraded to Buy from Neutral at Longbow), JCP +3.1% (upgraded to Overweight from Neutral at Piper Jaffray ), REXX +1.7% (initiated with a Outperform at Northland Capital), RVBD +1.4% (upgraded to Hold from Underperform at Jefferies), DD +1.4% (upgraded to Buy from Neutral at BofA/Merrill), MCD +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley), JNJ +0.6% ( upgraded to Buy from Hold at Jefferies), AET +0.4% ( upgraded to Outperform from Neutral at Credit Suisse)
M&A news: MCK +4% (McKesson makes best and final offer for Celesio, increasing offer price to EUR 23.50), FNSR +0.2% (Finisar to acquire u2t Photonics AG).
A few Brazil names are higher: OIBR +3%, CZZ +1.7%, TEF +1.6%, BBVA +1.5%
Other news: ICPT +114.1% (01/09 announces NASH Primary endpoint met: FLINT trial stopped early for efficacy based on highly statistically significant improvement in liver histology), CRDC +57.4% (receives 510(k) Clearance For MicroCutter XCHANGE 30 Cutting/Stapling Device), SQNM +13.8% (announces issuance of European patent for novel methods of detecting fetal aneuploidy),SGMO +13.6% BIIB +0.7% (Biogen Idec and Sangamo announce exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin), FRO +10.6% (still checking), TGB +4.2% (announces 35% increase in annual copper production), GALE+4.2% (continued strength), FRX +3.5% (Barron's profiles positive view on Forest Labs), YPF +2.9% (following late sell-off), ATHX +2% (has been granted patents from the Japan Patent Office for several inventions involving its proprietary cell therapy technology), NOK +1.7% (still checking), ACT +1.6% (generic version of Micardis receives FDA approval), GSK +1.5% (gains accelerated FDA approval for combination use of Mekinist and Tafinlar ), RYAAY +1.3% (still checking), JWN +1.2% (following M guidance/news), GG +1.2% ( achieves 2013 gold production forecasts; record Q4 production), F +1% (Increases Quarterly Dividend 25% in 2014 Q1 to $0.125/share, up from $0.10/share), DDD +0.9% (announced that will.i.am, global entertainer, entrepreneur and philanthropist, joined 3DS as its Chief Creative Officer), NVS +0.6% (higher despite Attorney General Eric Schneiderman announced that his office has filed a lawsuit; also may face Japan probe over its drug advertising, according to reports), BMY +0.5% (Bristol-Myers and AstraZeneca confirm FDA approval of Farxiga), AMZN +0.5% (reports more than a billion units worldwide were ordered from Marketplace Sellers this year), AIG +0.4% (extends tax asset protection plan), S +0.3% (spiked into the close on TMUS halt, downgraded to Hold from Buy at Deutsche Ban).
Analyst comments: ANGI +7.3% (upgraded to Strong Buy from Outperform at Raymond Jame), WWAV +3.3% (ticking higher, upgraded to Buy from Neutral at Longbow), JCP +3.1% (upgraded to Overweight from Neutral at Piper Jaffray ), REXX +1.7% (initiated with a Outperform at Northland Capital), RVBD +1.4% (upgraded to Hold from Underperform at Jefferies), DD +1.4% (upgraded to Buy from Neutral at BofA/Merrill), MCD +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley), JNJ +0.6% ( upgraded to Buy from Hold at Jefferies), AET +0.4% ( upgraded to Outperform from Neutral at Credit Suisse)